We studied the cytokine profile and the immune responses to thyroid antigens of specific T cell clones (TCC) isolated from patients with Hashimoto's thyroiditis (HT) and Graves' disease (GD). Antigen-specific TCC were reactive to thyroid peroxidase (TPO), thyroglobulin (Tg) or human recombinant TSH-receptor extracellular domain (TSH-R), and/or their respective peptides. Of the 43 clones derived from HT patients, 65% were reactive to TPO, and 59% of the 32 clones derived from GD patients were reactive to TSH-R. TPO epitopes 100 -119 and 625-644 were recognized by 75% of HT-derived clones, whereas TSH-R epitopes 158 -176, 207-222, and 343-362/357-376 were recognized by 85% of GD-derived TCC.
B
ASED on their cytokine production, naive, activated, and memory CD4 ϩ helper T cells (Th) have different functions at each developmental stage, and promote normal and pathological immune responses. Chronic stimulation of T cells leads to the development of Th0 cells, which release a wide range of cytokines, and may differentiate into Th1 or Th2 cells with more restricted cytokine production. Th1 cells release interleukin-2 (IL-2), interferon-␥ (IFN-␥), and tumor necrosis factor-␤ (TNF-␤), mediating delayed-type hypersensitivity and macrophage activation and opsonizing antibody production (such as IgG2a and IgG2b in mice). Th2 cells release IL-4, IL-5, IL-6, IL-10, and IL-13, stimulate IgA and IgE and nonopsonizing antibody production, and support the development and degranulation of eosinophils and mast cells. In addition, both Th1 and Th2 subsets produce IL-3, TNF-␣, and granulocyte-macrophage colony-stimulating factor (1, 2) . The expression of some cytokines such as IL-2, IL-10, and IL-13 are less restricted in humans (3, 4) . The development of Th1 and Th2 cells from Th0 cells is regulated by factors such as the nature of antigen, the type of antigenpresenting cells (APCs), the costimulatory molecules, and the interaction of cytokines. IL-4 promotes the differentiation of Th2 cells and, similar to IL-10, inhibits cytokine secretion by Th1 cells. On the other hand, IFN-␥ and IL-12 promote the generation and proliferation of Th1 cells, and down-regulate Th2 cell responses (except for IL-12, which stimulates IL-10 secretion) (2, 5) . A similar dichotomy exists in CD8 ϩ cells (5, 6) .
The predominance of Th1 or Th2 cells varies from one disease to another, and may promote different immunopathological responses. Thus, Th1 responses appear to be involved in organ-specific autoimmunity, e.g. autoimmune thyroiditis, rheumatoid arthritis, and diabetes mellitus, as well as in contact dermatitis, whereas Th2 responses are predominant when single or multiple environmental antigens trigger allergic atopic disorders, or in certain autoimmune disorders such as bullous and chronic graft-vs.-host diseases. This Th1/Th2 polarization is not apparent in some other autoimmune diseases (4, 7, 8) .
Helper and/or cytotoxic T cells with Th1-like and/or Th2-like responses may be involved in autoimmune thyroid disease (AITD), but their specific pathogenic roles are unclear. AITD is an organ-specific autoimmunity, characterized by thyroid tissue destruction in both Hashimoto's thyroiditis (HT) and atrophic thyroiditis, or by thyroid-stimulating antibodies leading to thyroid hyperfunction in Graves disease (GD). The major antigenic proteins involved in the pathogenesis of AITD include thyroid peroxidase (TPO), thyroglobulin (Tg), and TSH-receptor (TSH-R). Although TSH-R is the main antigen involved in the pathogenesis of GD, TPO is believed to be the pathogenic antigen in HT (9) .
We previously reported that several immunogenic sites on TPO or TSH-R molecules are recognized by peripheral and thyroid T cells, as well as by specific T cell lines in AITD (10 -13) . In the present study, we investigated the cytokine profile of specific T cell clones (TCC) derived from peripheral lymphocytes (PL) and thyroid lymphocytes (TL) in AITD, as well as the immunogenic T cells epitopes on TPO or TSH-R molecules recognized by these clones.
Materials and Methods Subjects
Peripheral blood mononuclear cells (PBMC) were obtained by FicollHypaque gradient centrifugation from seven patients with GD (assigned nos. 1-7), seven patients with HT (assigned nos. 8 -14) , and four controls [two with colloid nodular disease (CND) and two normal subjects]. Blood samples from patients with GD were collected before and/or during treatment with propylthiouracil and/or after 131 I or thyroidectomy. All patients with HT were receiving T 4 replacement therapy. TL were obtained at the time of thyroidectomy from four patients with GD, three patients with HT, and a patient with CND, and isolated as previously described (14) . Patients with AITD, but none of the controls, were positive by hemagglutination assay for TPO and/or Tg antibodies.
Thyroid antigens
Crude TPO, Tg, and the extracellular domain (amino acid residues 19 -417) of human recombinant TSH-R were obtained as previously described (11, 14, 15) . A panel of TPO and TSH-R peptides was selected based on amphiphilic analysis of human TPO and TSH-R sequences, respectively, and our previous experiments (10 -13) . The peptides were synthesized by a solid-phase peptide synthesis method (16) , and were all verified by direct sequencing. The peptide amino acid residues were as follows : for TPO: 100 -119, 114 -126, 211-223, 261-275, 420 -434, 556 -575, 625-644, 708 -727 and 882-901; and for TSH-R: 44 -62, 145-163,  158 -176, 207-222, 227-242, 237-252, 248 -263, 343-362, 357-376 and 385-404 . Tg peptide 2746 -2765 was also included.
TCC
PBMC (2 ϫ 10 6 /mL) were cultured in 2 mL RPMI-1640 (Gibco, Grand Island, NY) containing heat-inactivated 5% human serum, 100 U/mL penicillin-G (Gibco), 100 mg/L streptomycin (Gibco), 50 mol/L 2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO), and 1% nonessential-amino acids (Gibco) with 10 g/mL TPO or 5 g/mL TSH-R. After 7 days of stimulation, new medium and 20 U/mL recombinant human IL-2 (a generous gift from Cetus Corp., Emeryville, CA) were added for an additional 3-5 days. Cycles of restimulation with antigen and irradiated autologous PBMC as APC plus IL-2 were repeated twice. After three stimulation cycles, the cells were plated in 96-well U-bottom plates (Nunc, Roskilde, Denmark) by limited dilution at 1 cell/well, plus 10 g/mL TPO or 5 g/mL TSH-R and in the presence of 20 U/mL IL-2 and irradiated autologous PBMC (1 ϫ 10 5 cells/well). The frequency of growing cells always remained Ͻ25%. After 2-3 weeks, the clones were transferred to 24-well plates and expanded with phytohemagglutinin-P (1 g/mL, Sigma Chemical Co.) and 20 U/mL IL-2 in the presence of irradiated allogeneic PBMC. TL were cultured with IL-2 for 5 days, and then cloned with antigen as described above.
Microproliferation assay
TCC (1 ϫ 10 4 /well) were used in a 3-day proliferation assay. The cells were cultured with TPO (10 g/mL), Tg (20 g/mL), TSH-R (5 g/mL), TPO or TSH-R peptides (10 g/mL), purified protein derivative of tuberculin (5 g/mL; Parke Davis, Morris Plains, NJ), or tetanus toxoid (4 g/mL; a generous gift from Wyeth Labs., Marietta, PA) in duplicate or triplicate in 96-well plates. Irradiated autologous PBMC (1 ϫ 10 5 / well) were used as APC. These cultures were pulsed with [ 3 H]thymidine (1 Ci/well, SA 6.7 Ci/mmol; ICN Radiochemicals, Irvine, CA) for 16 -18 h. A proliferative response to antigen was considered significant when the stimulation index (SI) was Ն3. (SI: mean counts per minute in the presence of antigen/mean counts per minute in culture medium alone). This SI was found to clearly segregate results from normal controls and patients with AITD in several prior studies (11) (12) (13) .
Determination of cytokine production
T cell clones (1 ϫ 10 6 /well) were stimulated with immobilized anti-CD3 monoclonal antibodies (mAb) (1 g/mL) in the presence of irradiated JY line (Epstein-Barr virus-tranformed B cells; 1 ϫ 10 6 /well), as B7-expressing accessory cells, in 24-well plates. Supernatants were collected 48 h later and assayed for IL-2, IL-4, IL-5, IL-10, TNF-␤, and IFN-␥ by sandwich enzyme-linked immunosorbent assay (ELISA) in duplicate. Briefly, mAb pairs from Pharmingen (San Diego, CA) were used to measure IL-4 (sensitivity 0.1 ng/mL), IL-5 (sensitivity 0.4 ng/mL), and IL-10 (sensitivity 0.4 ng/mL). Mouse mAb and polyclonal rabbit antibody pairs were used for detection of IL-2 (sensitivity 0.4 U/mL) with capture mAb B-G5 (Biosource, Camarillo, CA) and polyclonal rabbitanti-recombinant human (rh) IL-2 (Genzyme, Cambridge, MA); for TNF-␤ (sensitivity 0.4 ng/mL) with capture mAb LTX-21 and polyclonal rabbit-anti-rhTNF-␤ (Endogen, Boston, MA); and for IFN-␥ (sensitivity 0.4 ng/mL) with capture mAb B-B1 and polyclonal rabbit-anti-rhIFN␥ (Biosource). Ninety-six well plates were coated with capture mAbs (1-4 ng/mL) overnight at 4 C. On the following day, the plates were washed and blocked with 3% BSA in PBS at room temperature for 2 h. The plates were subsequently washed, and standards (50 L), as well as samples (50 L), were added to wells and incubated overnight at 4 C. For the Pharmingen ELISA, avidin-peroxidase (Sigma) and 2,2Јazino-bis(3-ethylbenzo-thiazoline-6-sulfonic acid) (Sigma) were used to visualize cytokine detected with biotinylated secondary mAb (1-3 ng/mL), as per the Pharmingen protocol. Goat antirabbit Ig-alkaline phosphatase (Pierce, Rockford, IL) and p-nitrophenyl phosphate disodium salt (Pierce) were used to visualize the cytokines detected by the polyclonal IL-2, TNF-␤, and IFN-␥ antibodies (17) .
Flow cytometry
Immunofluorescence analysis was performed on T cells using unlabeled mAb to CD3, CD4, and CD8 molecules and an fluorescein isothiocyanate (FITC)-labeled polyclonal goat antimouse antibody as a second step reagent. The lymphocytes were analyzed by fluorescenceactivated cell sorting scan (FACS) (Becton Dickinson, Mountain View, Ca).
Statistical analysis
All results are given as mean Ϯ sd. Statistical analysis was performed by ANOVA, 2 contingency tables, and Fishers' exact probability method.
Results

TCC responses to thyroid antigens in patients with AITD
Three hundred clones were isolated from peripheral (PL) and/or thyroid (TL) lymphocytes of 14 patients with AITD. Seventy four antigen-specific clones were reactive to TPO, Tg, or TSH-R, and a single clone was reactive to TPO and Tg. The rest were considered nonspecific because they were either reactive to more than one peptide or nonreactive to any thyroid antigen. Of the 43 TCC established from HT patients (assigned nos. 1-44), 65% were reactive to TPO, and the rest were reactive to TSH-R (16%), Tg (16%), or TPO and Tg (2%, TCC 39). Of the 32 TCC derived from GD patients (assigned nos. 1-32), 59% were reactive to TSH-R and 41% to TPO (Fig.  1) . Clones with positive responses to TPO, Tg, or TSH-R molecules had SI of 4.2 Ϯ 1.9, 5.4 Ϯ 2.9, or 4.3 Ϯ 1.6 (means Ϯ sd; ranging from 3-12), respectively. The selection of TPO and TSH-R peptides for the microproliferation assays was based on our previous results (11 -13) . TPO epitopes, 100 -119 and 625-644, were recognized by 75% of clones established from HT patients, whereas TSH-R epitopes 158 -176, 207-222, and 343-362/357-376 were recognized by 85% of TCC established from GD patients (P Ͻ 0.005; Figs. 2 and 3 ). Fourteen percent of these clones were reactive to whole protein alone, 40% were reactive to native or recombinant proteins and their respective peptides, and 46% were reactive to a peptide but not to the whole protein. Because only 9 TPO peptides and 10 TSH-R peptides were evaluated, some nonspecific clones and TCC reactive only to the whole protein may actually be reactive to epitopes not included in this analysis.
TCC responses to thyroid antigens in controls
PL and/or TL from two normal controls and two patients with CND were reactive to TPO epitopes 114 -126, 211-223, 261-275, or 882-901 (data published in Ref. 11). Sixty eight clones were established from these controls. Although it should in theory be possible to develop antigen-specific T cell clones reactive to TPO or TSH-R epitopes, these clones were nonspecific and showed an autologous mixed lymphocyte reaction.
T cell phenotype
The phenotypes of the TCC were CD3 ϩ , CD4 ϩ , and CD8
Ϫ , except for one CD3 ϩ CD4 Ϫ and CD8 ϩ clone.
Cytokine production
According to their cytokine profile, the TCC were classified into Th0-like cells (secreting IL-4, IL-5, and IFN-␥), Th1-like cells (secreting IFN-␥), and Th2-like cells (secreting IL-4 and/or IL-5). Almost all of the 24 nonspecific TCC derived from thyroid tissue were Th1 cells in both GD and HT. Of the 54 specific clones, 17 (32%) were Th0, 26 (48%) were Th1, and the rest (20%) were Th2 cells. These clones were reactive to TPO, Tg, or TSH-R and their respective peptides, except for TCC 39, which was reactive to both TPO and Tg. The specific TCC derived from patients with HT were preferentially Th1 (55%), whereas in GD, both Th0 (43%) and Th1 (39%) were present ( Table 1, Fig. 4) .
Fifty three percent of Th0 were derived from GD patients and were reactive to TSH-R (P Ͻ 0.05). These clones synthesized a wide range of cytokines including IL-2, IL-4, IL-5, IL-10, IFN-␥, and TNF-␤. The majority of Th1 clones (50%) were derived from HT patients and were reactive to TPO or Tg (P Ͻ 0.05). All of these clones produced IFN-␥ (Tables 1,  2 , and 3). IL-2 was detected in only a few clones, probably because the supernatants were collected at 48 h of culture when IL-2 had been already consumed. IL-10 was also produced by 19% of these clones. Most Th1 clones specific for TPO or Tg and derived from HT thyroid tissue produced higher levels of IFN-␥ than other thyroid-specific Th1 clones (P Ͻ 0.05; Fig. 5 ). Eighty-two percent of Th2 clones were reactive to TPO and were established from peripheral blood (P Ͻ 0.05). All these clones secreted IL-5, and 64% of them produced IL-4 and IL-10. TNF-␤ was also produced by both Th1 and Th2 clones.
Discussion
In this study, TCC derived from PL and TL in patients with AITD, but not in controls, recognized TPO, Tg, or TSH-R antigens. Seventy three percent of clones reactive to TPO or Tg were derived from patients with HT, and 73% of clones FIG. 1. TCC reactivity to thyroid antigens and their respective peptides. Seventy five clones derived from PL or TL were reactive to TPO, Tg, or TSH-R. Of 43 TCC derived from HT patients, 28 were reactive to TPO, and the rest were reactive to TSH-R, Tg, or TPO and Tg. Of 32 TCC derived from GD patients, 19 were reactive to TSH-R, and the rest were reactive to TPO (upper). Most TCC isolated with TPO were reactive to amino acid residues 100 -119 and 625-644 of TPO, whereas TCC developed with TSH-R were mostly reactive to amino acid residues 158 -176, 207-222. and 343/357 of TSH-R (middle and lower, respectively). Almost all clones reactive to TPO peptide 100 -119 were derived from patients with HT, whereas TSH-R peptides 158 -176 and 207-222 were only recognized by clones derived from GD patients.
reactive to TSH-R were obtained from GD patients, supporting the importance of these antigens in HT and GD, respectively. However the data also clearly indicate the similarity of the immune responses in HT and GD, because clones reactive to TPO and TSH-R were developed from each group of patients. The predominant immunogenic TPO and TSH-R epitopes were located on amino acid residues 100 -119 and 625-644 TPO and 158 -176, 207-222, and 343-362/357-376 (TSH-R), respectively. TSH-R peptides 343-362 and 357-376 share a common sequence of six amino acids, which bridges the sequence of 357-362. Some clones were reactive to both peptides, suggesting that this site is an immunogenic T cell epitope.
There are short homologous epitopes shared by TPO and Tg. For instance TPO peptide 114 -126 and Tg peptide 2746 -2765, share a common epitope, which is also present in some Escherichia coli proteins (18) . Thus it is not surprising that single clones can react to both antigens (19) . Although the presence of a shared epitope suggests a mechanism for antigen-spreading from an environmental antigen or another thyroid antigen, it has not been proven that these homologies have pathogenic role in AITD. Clone 39 (from an HT patient) with Th1 phenotype (secreting IFN-␥) also recognized both TPO and Tg, but not the common epitope shared by TPO peptide 114 -126 and Tg peptide 2746 -2765, or any other peptide tested. This clone may contain more than one population, react to a different common T cell epitope, or least likely, bear more than one T cell receptor.
Multiple TPO and TSH-R T cell epitopes have been detected in primary lymphocyte cultures from patients with GD and HT (10, 12, 20 -23) . We previously demonstrated that amino acid residues 100 -119 and 625-644 of TPO molecule were recognized by TL and PL from patients with AITD but not by lymphocytes from normal controls (11) . A similar sequence (amino acid residues 632-645 of TPO) was also reported to be recognized by clones derived from a patient with GD (24) . Using lines and/or primary cultures, other studies have also demonstrated that TSH-R peptides 158 -176, 207-222, and 343-362/357-376 were recognized by T cells from patients with GD and were statistically significant when compared with control groups (12, 13, 23) . TSH-Rspecific clones have been recently identified using autoantigen-transfected Epstein-Barr virus-transformed B cell lines, but the location of TSH-R epitopes has not been determined (25) .
In this study, most clones reactive to amino acid residues 100 -119 of TPO molecule were derived from HT patients. Amino acid residues 158 -176 and 207-222 of TSH-R molecule were only recognized by clones derived from GD patients. TPO peptide 625-644 and TSH-R peptide 343-362/ 357-376 were recognized by clones derived from both GD and HT patients. Although the number of clones were limited, these results suggest that the 100 -119 residue is an important TP0 epitope involved in HT, whereas amino acid residues 158 -176 and 207-222 are the TSH-R epitopes in- a Difference in frequency between clones derived from GD or HT and their antigen recognition and cytokine profiles using a 2 contingency table was significant; P Ͻ 0.05.
FIG. 4. T cell subsets in AITD.
Percentages of TCC with Th0, Th1, or Th2 cytokine profiles in GD and HT are shown in upper panel. Numbers of TCC according to their source and cytokine pattern are shown in lower panel. Over all, 55% of clones isolated from patients with HT were Th1 cells, and most were isolated from TL (P Ͻ 0.05), whereas in GD Th0 (43%) and Th1 (39%) were equally predominant. Most Th2 clones were isolated from PL and were reactive to TPO (P Ͻ 0.05).
volved in GD. The other three peptides to which the clones reacted may also play a pathogenic role in GD and/or HT.
The fact that a percentage of clones from AITD patients were reactive to both a peptide and whole protein, proves that some of these synthetic peptides may contain naturally formed epitopes. Another interesting point is the finding of clones that were reactive to a peptide but not to the whole protein. The underlying reason for this phenomenon is unclear. These peptides are most likely cryptic epitopes, being residues that were inefficiently processed and presented to the developing immune system, and thus remain poor tolerogens (26, 27) One or more immunodominant determinants may be recognized in the early stage of disease. Subsequently, determinants could spread intra-and intermolecularly and lead to a diverse repertoire in the late stage of disease (26) . Because GD is characterized by cycles of remission and recurrence of variable duration and HT is progressive, and because our studies involved patients with established AITD, it is possible that the epitopes we identified here represent those involved in the late stage of AITD.
There is some evidence that Th1 cells are predominant in HT, whereas T cells with a less restricted range of cytokines are present in GD. The results differed from one study to another depending on the techniques used. Methods used to demonstrate these differences included immunohistochemical staining of cytokines present in thyroid tissues (such as IFN-␥), analysis of cytokine messenger RNA (mRNA) expression in thyroid tissues or TL using in situ hybridization or RT-PCR amplification, and isolation of T cell clones from PL and/or TL (25, 28 -32) . In most studies, T cell clones derived from patients with HT and/or GD were isolated with polyclonal activators, and their antigen specificity was not evaluated (30 -32) . The cytokine phenotype of these clones were not well defined, and contradictory results may have been obtained because of their nonspecific activation.
In our experiments, the clones were isolated with specific antigens and classified into Th0, Th1, and Th2 subsets. The predominant isolation of Th1 clones could be related to the type of APC (mostly monocytes) or IL-2 used for cloning, which to some extent may cause a preferential expansion of Th1 cells (2) . Our protocol for developing clones did not include IL-4, and this might have caused a panel of TCC in which Th2-type cells are underrepresented. Clones derived from patients with HT preferentially had Th1 phenotype, whereas clones derived from patients with GD were predominantly Th0 and Th1. Antigen-specific T cells with Th0 phenotype as the major population have also been described in other autoimmune disorders (4, 33) . Thus, it is not surprising that Th0 cells are also predominat in GD. The presence of IL-2, IFN-␣, and IFN-␥ mRNA, and the absence of IL-4 mRNA in TL from GD patients, indicate that Th1 cells are also an important subset in GD (28) . The predominance of nonspecific clones with Th1 pattern and the detection of a few specific TSH-R clones with Th0 and Th2 profiles isolated from a GD thyroid tissue has also been described (25) . In our study, nonspecific clones derived from GD thyroid tissues were also Th1, whereas TSH-R specific clones were predominantly Th0 and Th1, and a single clone was Th2.
Most Th2 clones that induce nonopsonizing antibodies were isolated from peripheral blood, whereas the harmful Th1 cells, which induce opsonizing antibodies and cellmediated responses, were predominantly recovered from thyroid (target) tissues. The predominance of Th1 cells in the thyroid tissue may be related to their thyroid-specific homing receptors (34) .
Th1 clones, derived from HT thyroid tissue and reactive to TPO or Tg, produced high levels of IFN-␥. This proinflammatory cytokine, promotes activation of macrophages, production of TNF-␣, IL-1, IL-6, and reactive oxygen. Thus these Th1 cells appear to be highly inflammatory, contributing to thyroid tissue destruction. IL-1␤ is secreted by activated macrophages or thyrocytes and can induce thyrocyte apoptosis through Fas-Fas ligand interaction. This seems to be a major pathogenic mechanism of tissue damage in HT (35) . Therefore, Th1 cells in cooperation with macrophages and natural killer cells may indirectly induce thyrocyte apoptosis by promoting IL-1␤ production through INF-␥.
IL-10, which inhibits macrophage activation and T cell proliferation, was produced by Th0, Th1, and Th2 clones. The highest production of IL-10 was obtained from Th2 clone supernatants (3.5 Ϯ 2.1 ng/mL; mean Ϯ sd). It has been suggested that the function of Th1 cells as proinflammatory or antiinflammatory may depend on the ratio of IFN-␥ or IL-2 to IL-10 (36). In our study, 19% of Th1 clones produced both IFN-␥ and to a lesser extent IL-10. Even small amounts of IL-10 produced by these clones could inhibit the function of the typical Th1 cells, which produce IL-2 and IFN-␥ but not IL-10.
Thyrocytes are not innocent target cells. They produce TNF, TGF-␤, IL-1, IL-6, and IL-8 and express human histocompatability leukocyte antigen classes I and II, as well as costimulatory and adhesion molecules such as intercellular adhesion molecule-1 and lymphocyte function-associated molecule-3, regulated by cytokines or other factors, which in return can induce and/or modulate the cytokine production of T cells. Thyrocytes can function as APC, present their own antigens, and maintain the activation of autoreactive T cells, via aberrant expression of human histocompatability leuko- cyte antigen class II molecules as a result of local production of IFN-␥ by lymphocytes, up-regulation of costimulatory molecules, and production of cytokines such as IL-1 and IL-6. This may contribute to the pathogenesis and perpetuation of AITD (9) .
Our findings suggest that some of the immunodominant T cell epitopes are located on amino acid residues 100 -119 and 625-644 of TPO in HT and amino acid residues 158 -176, 207-222, and 343-362/357-376 of TSH-R in GD. This study further demonstrates that thyroid-specific T cells can be divided into Th0, Th1, and Th2 subsets on the basis of their cytokine profiles, and that these cytokines may be involved in the pathogenesis of AITD, leading to thyroid tissue destruction by Th1 cells in HT and stimulation of TSH-R autoantibody production by Th0 cells in GD. Based on these observations, newer therapeutic and preventative approaches may be designed to modify the cytokine profiles of autoreactive T cells to suppress, inhibit, or even reverse the autoimmune process. However, these approaches should be undertaken with certain precautions. The induction of antigen-specific immune tolerance and suppression of experimental autoimmune diseases by parenteral or oral administration of antigen can, at times, exacerbate the autoimmune process rather than suppress it. Under some conditions, the protecting Th2 cells can enhance the production of pathogenic autoantibodies and aggravate the disease (37, 38) .
